Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Barnes & Noble Education, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][3]. Financial Disclosure - On July 18, 2025, Barnes & Noble disclosed that there may be an overstatement of up to $23.0 million in its accounts receivable balance as of the fiscal year-end on May 3, 2025, due to issues related to the recording of digital sales costs [3]. - Following this disclosure, Barnes & Noble's share price fell by $2.36, or approximately 21%, closing at $8.87 per share on July 21, 2025 [3]. Legal Context - The investigation by Kirby McInerney LLP focuses on whether Barnes & Noble and/or its officers have engaged in unlawful business practices that could affect shareholders [1][4]. - The law firm specializes in securities litigation and has a history of recovering billions of dollars for shareholders [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Petco Health and Wellness Company, Inc. securities between January 14, 2021, and June 5, 2025, of the upcoming lead plaintiff deadline on August 29, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Petco securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that throughout the Class Period, defendants made false and misleading statements regarding Petco's business model and pandemic-related growth, which were unsustainable [5]. - It is claimed that the strength of Petco's differentiated product strategy was overstated, and the true scope of issues affecting the company was downplayed [5]. - The lawsuit asserts that defendants overstated Petco's ability to deliver sustainable, profitable growth, leading to investor damages when the true details became public [5].

MILWAUKEE, July 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Synovus (NYSE: SNV) for possible breaches of fiduciary duty and other violations of law in its transaction with Pinnacle Financial Partners.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.In the transaction, shareholders of Synovus will receive shares of a new Pinnacle parent company based on a fixed ...

Bragar Eagel & Squire, P.C. Litigation Partners Encourage Investors Who Suffered Losses In Fortrea Holdings (FTRE) To Contact Them To Discuss Their Options If you purchased or acquired securities in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) --  Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law ...

ATLANTA, July 23, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) complied with federal securities laws. On July 22, 2025, Telix disclosed that the Company “received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.” Following th ...

Group 1 - A class action has been filed against Centene Corporation on behalf of investors who acquired its securities between December 12, 2024, and June 30, 2025 [1] - The allegations state that Centene misled investors about its business prospects, particularly regarding projected revenue and enrollment rates [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a significant stock price decline of over 40% from $56.65 to $44.78 per share [3] Group 2 - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5] - Interested parties can sign up for notifications regarding the class action settlement or alerts on corporate wrongdoing [6]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their OptionsIf you purchased or otherwise acquired stock of Alto (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, 2024 (the "IPO" or "Offering"); and/or (b) Alto securities between February 2, 2024 a ...

Core Viewpoint - Neogen Corporation is facing a securities class action lawsuit for failing to disclose material information during the class period from January 5, 2023, to June 3, 2025, which has led to significant financial losses for investors [1][3]. Company Performance - On April 9, 2025, Neogen reported a quarterly revenue decrease of 3.4% to $221 million, attributed to integration issues, and lowered its FY25 guidance, anticipating capital expenditures of $100 million due to reduced adjusted EBITDA and integration-related costs [4]. - Following the revenue report, Neogen's share price dropped 28% to close at $5.02 per share on a volume of 47 million shares [4]. - On June 4, 2025, the company projected an EBITDA margin in the high-teens, a significant decline from the previous quarter's profit margin of 22%, resulting in an additional 17% drop in share price to close at $4.96 per share [4]. Legal Context - The lawsuit is titled Operating Eng'rs Constr. Indus. & Misc. Pension Fund v. Neogen Corp., et al., No. 25-cv-00802, and is pending in the United States District Court for the Western District of Michigan [5]. - Investors who purchased shares during the class period have until September 16, 2025, to file lead plaintiff applications [1][2].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences Holdings, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during a specified class period [1][3]. Group 1: Company Financial Issues - On February 25, 2025, Maravai announced a postponement of its fiscal 2024 earnings release and the filing of its annual report due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [2]. - The company identified a material weakness in its internal controls over revenue recognition and required additional time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC [2]. - Following this announcement, Maravai's share price fell by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, amid unusually heavy trading volume [2]. Group 2: Class Action Allegations - The class action complaint alleges that Maravai's management made materially false and misleading statements and failed to disclose adverse facts about the company's operations and prospects [3]. - Specific allegations include inadequate internal controls over financial reporting related to revenue recognition, inaccurate revenue recognition during fiscal 2024, and overstated goodwill [3]. - The complaint asserts that the positive statements made by the defendants regarding the company's business lacked a reasonable basis due to these undisclosed issues [3].

Vicor (VICR) Q2 2025 Earnings Call July 22, 2025 05:00 PM ET Company ParticipantsJames Schmidt - Corporate VP, CFO, Treasurer & SecretaryPhilip Davies - Corporate VP - Global Sales & MarketingPatrizio Vinciarelli - Chairman, President & CEOJon Tanwanteng - Managing DirectorJames Liberman - Financial AdvisorDonald McKenna - Financial AdvisorConference Call ParticipantsQuinn Bolton - Senior AnalystRichard Shannon - Senior Research AnalystNone - AnalystOperatorHello, and welcome to Vicor's Second Quarter Earni ...